Renata Zajączkowska
Jagiellonian University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Renata Zajączkowska.
Neurologia I Neurochirurgia Polska | 2014
Andrzej Szczudlik; Jan Dobrogowski; Jerzy Wordliczek; Adam Stępień; Małgorzata Krajnik; Wojciech Leppert; Jarosław Woroń; Anna Przeklasa-Muszyńska; Magdalena Kocot-Kępska; Renata Zajączkowska; Marcin Janecki; Anna Adamczyk; Małgorzata Malec-Milewska
Neuropathic pain may be caused by a variety of lesions or diseases of both the peripheral and central nervous system. The most common and best known syndromes of peripheral neuropathic pain are painful diabetic neuropathy, trigeminal and post-herpetic neuralgia, persistent post-operative and post-traumatic pain, complex regional pain syndrome, cancer-related neuropathic pain, HIV-related neuropathic pain and pain after amputation. The less common central pain comprises primarily central post-stroke pain, pain after spinal cord injury, central pain in Parkinson disease or in other neurodegenerative diseases, pain in syringomyelia and in multiple sclerosis. A multidisciplinary team of Polish experts, commissioned by the Polish Association for the Study of Pain and the Polish Neurological Society, has reviewed the literature on various types of neuropathic pain, with special focus on the available international guidelines, and has formulated recommendations on their diagnosis and treatment, in accordance with the principles of evidence-based medicine (EBM). High quality studies on the efficacy of various medicines and medical procedures in many neuropathic pain syndromes are scarce, which makes the recommendations less robust.
Pharmacological Reports | 2018
Renata Zajączkowska; Barbara Przewlocka; Magdalena Kocot-Kępska; Joanna Mika; Wojciech Leppert; Jerzy Wordliczek
Tapentadol is a centrally acting analgesic with a dual mode of action as a μ-opioid receptor (MOR) agonist and a noradrenaline reuptake inhibitor (NRI). It was initially approved by the US Food and Drug Administration in November 2008 for the treatment of moderate-to-severe acute pain in adult patients, and in August 2011, for chronic pain in an prolonged release form in the same population. Due to its limited protein binding capacity, the absence of active metabolites and significant microsomal enzyme induction or inhibition, tapentadol has a limited potential for drug-drug interactions. It appears to be well-tolerated and effective in the treatment of moderate-to severe acute and chronic pain. Owing to its dual mechanism of action, it is hypothesized to be good option in the treatment of both nociceptive and neuropathic pain.
BÓL | 2018
Jerzy Wordliczek; Aleksandra Kotlińska-Lemieszek; Wojciech Leppert; Jarosław Woroń; Jan Dobrogowski; Małgorzata Krajnik; Anna Przeklasa-Muszyńska; Jacek Jassem; Jarosław Drobnik; Anna Wrzosek; Marcin Janecki; Jadwiga Pyszkowska; Magdalena Kocot-Kępska; Renata Zajączkowska; Iwona Filipczak-Bryniarska; Krystyna Boczar; Joanna Jakowicka-Wordliczek; Małgorzata Malec-Milewska; Andrzej Kübler; Marek Suchorzewski; Sylwester Mordarski
Guidelines for the pharmacotherapy of pain in cancer patients were developed by a group of 21 experts of the Polish Association for the Study of Pain, Polish Society of Palliative Medicine, Polish Society of Oncology, Polish Society of Family Medicine, and Polish Society of Anaesthesiology and Intensive Therapy. During a series of meetings, the experts carried out an overview of the available literature on the treatment of pain in cancer patients, paying particular attention to systematic reviews and more recent randomized studies not included in the reviews. The search was performed in the EMBASE, MEDLINE, and Cochrane Central Register of Controlled Trials databases using such keywords as “pain”, “cancer”, “pharmacotherapy”, “analgesics”, and similar. The overviewed articles included studies of pathomechanisms of pain in cancer patients, methods for the assessment of pain in cancer patients, and drugs used in the pharmacotherapy of pain in cancer patients, including non-opioid analgesics (paracetamol, metamizole, non-steroidal anti-inflammatory drugs), opioids (strong and weak), coanalgesics (glucocorticosteroids, α2-adrenergic receptor agonists, NMDA receptor antagonists, antidepressants, anticonvulsants, topical medications) as well as drugs used to reduce the adverse effects of the analgesic treatment and symptoms other than pain in patients subjected to opioid treatment. The principles of opioid rotation and the management of patients with opioidophobia were discussed and recommendations for the management of opioid-induced hyperalgesia were presented. Drugs used in different types of pain experienced by cancer patients, including neuropathic pain, visceral pain, bone pain, and breakthrough pain, were included in the overview. Most common interactions of drugs used in the pharmacotherapy of pain in cancer patients as well as the principles for the pharmacotherapy of pain in cancer patients with organ dysfunctions (circulatory failure, chronic obstructive pulmonary disease,
Polski Przegląd Neurologiczny | 2011
Jan Dobrogowski; Renata Zajączkowska; Julian Dutka; Jerzy Wordliczek
Polski Przegląd Neurologiczny | 2011
Jerzy Wordliczek; Renata Zajączkowska; Jan Dobrogowski
BÓL | 2018
Magdalena Kocot-Kępska; Renata Zajączkowska; Jan Dobrogowski; Anna Przeklasa-Muszyńska
Anestezjologia Intensywna Terapia | 2018
Hanna Misiołek; Renata Zajączkowska; Andrzej Daszkiewicz; Jarosław Woroń; Jan Dobrogowski; Jerzy Wordliczek; Radosław Owczuk
Anaesthesiology Intensive Therapy | 2018
Hanna Misiołek; Renata Zajączkowska; Andrzej Daszkiewicz; Jarosław Woroń; Jan Dobrogowski; Jerzy Wordliczek; Radosław Owczuk
Palliative Medicine in Practice | 2017
Renata Zajączkowska; Wojciech Leppert; Jerzy Wordliczek
Palliative Medicine in Practice | 2017
Jerzy Wordliczek; Renata Zajączkowska; Wojciech Leppert